Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Glaxo SmithKline

- PMLiVE

NICE knocks back Celgene’s Abraxane in pancreatic cancer

Says cancer drug's cost not justified by its limited benefit

- PMLiVE

Pharma and med tech companies form eye health group

The Industry Vision Group wants the NHS to make eye care a priority

Novartis building

Novartis’ Ultibro tops Seretide in comparative COPD trial

Will help Novartis position Ultibro as a corticosteroid-free alternative to GSK's blockbuster

Bristol-Myers Squibb (BMS) building

BMS takes PD-1 rivalry with Merck to the law courts

Claims Keytruda infringes antibody patents it holds with Ono Pharmaceutical

- PMLiVE

AbbVie forges $1.5bn ageing disease alliance with Calico

Pharma company partners with Google’s health research business

- PMLiVE

New eye indication for Allergan’s Ozurdex

EU approval extends the drug's use to diabetic macular oedema

- PMLiVE

BMS launches hepatitis C pill Daklinza in the UK

Will be offered as a combination treatment with Gilead's Solvadi

Novartis building

Novartis heart failure trial leads the buzz at ESC

Potential blockbuster LCZ696 cuts cardiovascular deaths by 20% versus standard therapy

- PMLiVE

Takeda: No link between Actos and bladder cancer

Ten-year study backs safety of diabetes drug

- PMLiVE

GSK Ebola vaccine to start safety studies

Will use volunteers in the US, UK and Africa

- PMLiVE

BMS can ride on Sovaldi’s success as Daklinza cleared in EU

Hepatitis C drug approved in combination with Gilead’s huge-selling treatment

- PMLiVE

Allergan agrees to shareholder meeting on Valeant bid

Pershing Square Capital convinces shareholders to request consultation

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links